Table 3.
Change from baseline to week 12 in Polycystic Ovary Syndrome Questionnaire total scores, intent-to-treat population
| PCOSQ domain | Mean (SE) total score | ||
|---|---|---|---|
| Placebo | Fezolinetant 60 mg | Fezolinetant 180 mg | |
| Emotions | |||
| Baseline | 4.57 (0.25) | 4.57 (0.27) | 4.78 (0.28) |
| Wk 12 change | −0.1 (0.17) | 0 (0.19) | −0.6 (0.29) |
| Body hair | |||
| Baseline | 3.97 (0.36) | 3.76 (0.39) | 4.06 (0.45) |
| Wk 12 change | −0.3 (0.17) | −0.1 (0.17) | −0.3 (0.26) |
| Weight | |||
| Baseline | 3.92 (0.42) | 3.74 (0.45) | 4.10 (0.41) |
| Wk 12 change | −0.3 (0.22) | −0.4 (0.19) | 0 (0.27) |
| Infertility problemsa | |||
| Baseline | 4.70 (0.36) | 4.37 (0.35) | 4.77 (0.39) |
| Wk 12 change | 0.1 (0.24) | 0.1 (0.26) | −0.6 (0.35) |
| Menstrual problems | |||
| Baseline | 4.38 (0.28) | 3.67 (0.30) | 4.14 (0.28) |
| Wk 12 change | 0.3 (0.26) | 0.6 (0.26) | 0.3 (0.30) |
Abbreviation: PCOSQ, Polycystic Ovary Syndrome Questionnaire.
a Participants were required to use contraception during the trial if they were sexually active. However, the PCOSQ was administered in full, including the 4 items relating to infertility.